BM-01

Ischemic Stroke: A Differentiated Drug-Delivery Opportunity

An Established Market in China. A Defined Clinical Entry Point. Broader Commercial Potential.

Contact BD About This Program

A Market Opportunity Built on Existing Treatment Demand

Acute ischemic stroke represents an established pharmaceutical treatment market in China, with commercially available injectable and non-injectable therapies.

However, no single administration route is ideally suited to every patient.

Stroke-related swallowing difficulties, impaired tongue coordination, and oral-motor limitations can create challenges for certain patients using conventional dosage forms.

These administration challenges provide a potential point of differentiation within existing treatment pathways.

For BM Pharma, this is a strategic entry point — not the limit of the program's commercial ambition.

The Product Development Opportunity

BM Pharma is advancing an early-stage, differentiated non-injectable drug formulation program for acute ischemic stroke.

Our strategy focuses on three complementary development opportunities.

1. A Focused Clinical Entry Point

Investigating an alternative administration approach for selected patients who may experience difficulties with conventional oral or sublingual administration.

2. Broader Competitive Potential

Exploring a differentiated treatment option for a wider, clinically eligible ischemic stroke population, with the long-term objective of competing within established pharmaceutical treatment markets.

Broader adoption will depend on demonstrated efficacy, safety, drug exposure, administration performance, and clinically meaningful value compared with available options.

3. Continuity Across Treatment Settings

Evaluating a treatment pathway that could begin early during hospital-based care and, where clinically appropriate and supported by evidence, continue beyond hospital discharge to complete a prescribed treatment course.

This approach remains subject to validation of the treatment window, dosing regimen, safety, and clinical benefit.

Development Progress

Initial formulation development and exploratory animal pharmacokinetic studies have been completed.

Ongoing development focuses on formulation optimization, comparative drug exposure, administration feasibility, and preclinical safety evaluation.

The next phase is intended to generate evidence supporting candidate selection, clinical development strategy, and meaningful product differentiation.

Why Partner Early?

This program offers pharmaceutical companies an opportunity to participate in the development of a differentiated product within an established therapeutic market.

Potential partners can contribute to shaping the development pathway while managing investment exposure through predefined technical and scientific milestones.

Collaboration opportunities include funded feasibility evaluation, milestone-driven co-development, and potential technology licensing and regional commercialization partnerships.

Explore a Partnership

Contact BD About This Program

Early-stage investigational program. Clinical efficacy, safety, comparative advantage, suitability for home administration, and broad patient applicability have not been established. The program is not intended to replace emergency reperfusion treatment.

Licensing & Co-Development

Our Integrated Licensing & Co-Development Model

One integrated agreement encompassing all four components

  1. Funded Feasibility Evaluation

  2. Technology Licensing

  3. Milestone Payments

  4. Sales-Based Royalties

Amounts, payment milestones, continued-development obligations and exit conditions are determined by the parties’ definitive agreement.

Contact BD About This Program

How to Start a Partnership

  1. 1. Introduce Your Company

    Email our Business Development team with a brief company introduction and the program of interest.

  2. 2. BD & Scientific Discussion

    Our BD team will coordinate an introductory discussion and involve relevant scientific or development specialists as appropriate.

  3. 3. Confidential Technical Review

    Following mutual interest, the parties may enter into a confidentiality agreement and exchange detailed technical information.

  4. 4. Integrated Partnership Agreement

    Potential collaboration is structured around funded feasibility evaluation, technology licensing, milestone payments and sales-based royalties under an integrated agreement.